cognitive cybersecurity intelligence

News and Analysis

Search

Shining Light on How Protagonist, Takeda Drug Brings Treatment of a Rare Blood Disease Out of the Dark Ages

Shining Light on How Protagonist, Takeda Drug Brings Treatment of a Rare Blood Disease Out of the Dark Ages

Protagonist Therapeutics’ drug rusfertide reduced the need for phlebotomies as a way to treat the rare blood cancer polycythemia vera. Longer-term Phase 3 data for the Takeda Pharmaceutical-partnered peptide drug were presented during the annual meeting of the American Society of Hematology.
The post Shining Light on How Protagonist, Takeda Drug Brings Treatment of a Rare Blood Disease Out of the Dark Ages appeared first on MedCity News.

Source: medcitynews.com –

Subscribe to newsletter

Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.

More Posts

CDMOs Expand and Build for Future Growth

CDMOs Expand and Build for Future Growth

The top contract development and manufacturing organizations (CDMOs) have been busy in recent months expanding their service offerings, building new facilities, and navigating how to